Belite Bio, Inc (BLTE)
Belite Bio is a San Diego drug developer working on oral treatments for degenerative retinal diseases that cause vision loss. It last closed at $157.72 on Nov 17, down 2.98% on the day. BLTE last reported earnings on Thu, Nov 12, 2026. The average 12-month price target from 4 analysts is $251.00 (+59.1% from the last close), with a high of $314.00 and a low of $215.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $1.8M, the largest $1.2M.
Key Stats
Fiscal 2025Not reported for this period.
From BLTE's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 31). Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on BLTE in the past 90 days. The average target is $251.00, with a high of $314.00 and a low of $215.00, compared with the last close of $157.72.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Canaccord Genuity | Target raised | Buy | $303 → $314 |
| Nov 16 | Mizuho | Target lowered | Buy | $234 → $230 |
| Nov 13 | Leerink Partners | Maintained | Buy | $215 |
| Sep 9 | Mizuho | Target raised | Buy | $215 → $234 |
| Sep 8 | HC Wainwright & Co. | Target raised | Buy | $214 → $245 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 1% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 51). The nearest support is the Pivot S1 at $155.42, and the nearest resistance the Pivot at $158.81.
| RSI (14) | 51.09 | Middle of its range | Neutral |
| MACD | 1.43 | Above its signal line | Bullish |
| Stochastic | 68.7 | Middle of its range | Neutral |
| ADX (14) | 18.6 | No clear trend | |
| Williams %R | -44.1 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 75.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +3.6% | Change over 10 sessions | Bullish |
| ATR (14) | $7.84 | Typical daily range, 5.0% of price |
| RSI (14) | 50.71 | Middle of its range | Neutral |
| MACD | 1.22 | Below its signal line | Bearish |
| Stochastic | 30.8 | Middle of its range | Neutral |
| ADX (14) | 26.1 | Trending up | |
| Williams %R | -71.0 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 0.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −9.3% | Change over 10 sessions | Bearish |
| ATR (14) | $15.82 | Typical daily range, 10.0% of price |
What happened before
See how BLTE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How BLTE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.
Whale Options Flow
90DNo whale options trades in BLTE in the last 90 days.
Dark Pool
30DBLTE Institutional Ownership
Full report →- ▲57 buying vs 42 selling
- ●Shares held by funds -0.6%
- ▲Funds holding +15
- ▼Superinvestors: 0 added, 4 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 96 | 81 | +18.5% |
| In funds' top 10 | 5 | 5 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 28 / 29 | 22 / 28 | +14.0% |
| Reduced / sold out | 30 / 12 | 22 / 17 | +7.7% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BLTE is in one of them and how their past BLTE trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BLTE in an article yet. Here's the latest on the wider market.
About Belite Bio
Belite Bio is a drug development company based in San Diego, California. It is developing tinlarebant, a tablet taken once a day, for people with degenerative retinal diseases that cause progressive vision loss, including geographic atrophy and Stargardt disease type 1. The company also has an earlier stage oral compound aimed at metabolic conditions such as fatty liver disease and type 2 diabetes. Its intended users are patients with these eye conditions and the doctors who would treat them if a product is approved.
- Headquarters
- San Diego, CA



